2-(4-iodophenyl)butyric acid | 99059-67-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(4-iodophenyl)butyric acid
• 英文别名: 2-(4-iodophenyl)butanoic acid；2-(4-Jod-phenyl)-buttersaeure；4-iodophenylbutyric acid；4-Iodophenyl butyric acid
• CAS: 99059-67-3
• 化学式: C₁₀H₁₁IO₂
• 分子量: 290.101
• InChiKey: XSHBGHWPKIESGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-iodophenyl)butyric acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-(4-Iodophenyl)butanoyl chloride
  参考文献：
  名称：

  路易斯酸催化双环[1.1.0]丁烷与乙烯酮的缩甲醛(3+2)-环加成反应

  摘要：

  提出了一种温和、高效且无过渡金属的方法，通过路易斯酸催化容易获得的双环[1.1.0]丁烷和乙烯酮的形式(3+2)-环加成来制备有价值的双环[2.1.1]己烷。双环[2.1.1]己烷核心3位上的官能团具有优异的耐受性和多种取代模式。

  DOI：

  10.1002/anie.202304771
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 potassium iodide 作用下， 生成 2-(4-iodophenyl)butyric acid
  参考文献：
  名称：

  The role of gender and family support on dietary compliance in an African American adolescent hypertension prevention study

  摘要：

  Social support experiences vary markedly across gender groups, and little is known about the role of social support in promoting healthy dietary compliance in African American adolescents who are at increased risk for developing hypertension. This study examined the relation between gender dietary social support, and compliance to a low sodium diet. Casual blood pressures were also examined in relation to dietary compliance and gender One hundred eighty-four healthy African American adolescents (83 boys, 101 girls) participated in an intensive 5-day low sodium diet (50 mEq/24 hr) as part of a hypertension prevention program. Emotional dietary social support from family members and friends was measured at baseline. Compliance was defined as urinary sodium excretion of less than or equal to 50 mEq/24 hr at postsodium restriction. The results indicated a significant Gender x Compliance effect for positive family support (p < .05). Girls who were compliant reported higher levels of dietary support from family members (19.2 +/- 7.8) than boys who were compliant (16.9 +/- 7.0). In contrast, boys who were compliant reported lower levels of dietary support from family members (16.9 +/- 7.0) than boys who were not compliant (20.2 +/- 7.5). Systolic blood pressure showed a trend toward decreasing in compliant participants (104.4 +/- 8.4 vs. 101.7 +/- 8.0, mm Hg, p < .06), but the effect diminished when Quetelet Index (kg/m(2)) was controlled for in the analyses (p < .12). These results suggest that higher levels of emotional dietary support from family members are associated with better adherence to short-term sodium restriction for African American girls as compared to boys. Further research is needed to determine the long-term impact of social support on sodium restriction in adolescent populations.

  DOI：

  10.1207/s15324796abm2301_9

文献信息

• [EN] METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES TROUBLES SENSIBLES AU RETINOIDE AU MOYEN D'INHIBITEURS SELECTIFS DE CYP26A ET DE CYP26B
  申请人：ALLERGAN INC

  公开号：WO2005058301A1

  公开（公告）日：2005-06-30

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了一种治疗患有视黄酸反应性障碍的个体的方法。在一个实施例中，一种方法包括向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A至少具有10倍的选择性。在另一个实施例中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，所述选择性CYP26A抑制剂的化学公式如说明书所述。本发明还提供了用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
• PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BELLEVERGUE Patrice

  公开号：US20110124643A1

  公开（公告）日：2011-05-26

  The present invention relates to pyridopyridone derivatives of formula (I): in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.

  本发明涉及公式（I）的吡啶吡啶酮衍生物，其中变量如本文所定义，涉及其制备以及作为PDGF（血小板源性生长因子）配体受体激酶活性抑制剂以及可能的FLT3（类似Fms酪氨酸激酶受体）配体受体的治疗用途。
• [EN] ARYL SUBSTITUTED OLEFINIC COMPOUNDS AS PDE10A INHIBITORS<br/>[FR] COMPOSÉS OLÉFINIQUES À SUBSTITUTION ARYLE EN TANT QU'INHIBITEURS DE LA PDE10A
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2011138657A1

  公开（公告）日：2011-11-10

  The present invention provides aryl substituted olefinic compounds as Phosphodiesterase 1 0A (PDE 1 0A) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 1 0A enzyme. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof.

  本发明提供了芳基取代烯烃化合物作为磷酸二酯酶1 0A（PDE 1 0A）抑制剂。具体来说，本文描述的化合物可用于通过抑制磷酸二酯酶1 0A酶来治疗或预防疾病、症状和/或紊乱。本文还提供了用于制备本文描述的化合物的工艺、用于合成的中间体以及它们的药物组合物。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Vasudevan Jayasree

  公开号：US20050176689A1

  公开（公告）日：2005-08-11

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  本说明书提供的1至17式化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。